248 related articles for article (PubMed ID: 34343186)
1. Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study.
Chan J; Gidding HF; Blyth CC; Fathima P; Jayasinghe S; McIntyre PB; Moore HC; Mulholland K; Nguyen CD; Andrews R; Russell FM
PLoS Med; 2021 Aug; 18(8):e1003733. PubMed ID: 34343186
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
[TBL] [Abstract][Full Text] [Related]
3. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
4. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
[TBL] [Abstract][Full Text] [Related]
5. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children.
Nair H; Watts AT; Williams LJ; Omer SB; Simpson CR; Willocks LJ; Cameron JC; Campbell H
BMC Infect Dis; 2016 Aug; 16():390. PubMed ID: 27506837
[TBL] [Abstract][Full Text] [Related]
6. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010.
Thoon KC; Chong CY; Tee NW
Int J Infect Dis; 2012 Mar; 16(3):e209-15. PubMed ID: 22281191
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children: a retrospective, population-based, record-linked cohort study.
Fathima P; Gidding HF; McIntyre PB; Snelling TL; McCallum L; de Klerk N; Blyth CC; Liu B; Moore HC
Lancet Child Adolesc Health; 2019 Oct; 3(10):713-724. PubMed ID: 31439496
[TBL] [Abstract][Full Text] [Related]
8. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013.
Martinelli D; Pedalino B; Cappelli MG; Caputi G; Sallustio A; Fortunato F; Tafuri S; Cozza V; Germinario C; Chironna M; Prato R;
Hum Vaccin Immunother; 2014; 10(1):33-9. PubMed ID: 24096297
[TBL] [Abstract][Full Text] [Related]
9. Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance.
; Mackenzie GA; Hill PC; Jeffries DJ; Ndiaye M; Sahito SM; Hossain I; Uchendu U; Ameh D; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Muhammad BS; Ahameefula E; Fombah AE; Adeshola B; Lobga BG; Saha D; Mackenzie R; Odutola A; Plumb ID; Akano A; Ebruke BE; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UN; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Fofana S; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
Lancet Infect Dis; 2021 Sep; 21(9):1293-1302. PubMed ID: 34280357
[TBL] [Abstract][Full Text] [Related]
10. Acute lower respiratory infections in Indigenous infants in Australia's Northern Territory across three eras of pneumococcal conjugate vaccine use (2006-15): a population-based cohort study.
Binks MJ; Beissbarth J; Oguoma VM; Pizzutto SJ; Leach AJ; Smith-Vaughan HC; McHugh L; Andrews RM; Webby R; Morris PS; Chang AB
Lancet Child Adolesc Health; 2020 Jun; 4(6):425-434. PubMed ID: 32450122
[TBL] [Abstract][Full Text] [Related]
11. Long-term Vaccine Impact on Invasive Pneumococcal Disease Among Children With Significant Comorbidities in a Large Australian Birth Cohort.
Jayasinghe S; Liu B; Gidding H; Gibson A; Chiu C; McIntyre P
Pediatr Infect Dis J; 2019 Sep; 38(9):967-973. PubMed ID: 31408056
[TBL] [Abstract][Full Text] [Related]
12. Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.
Gidding HF; Sheridan S; Fathima P; Moore HC; Liu B; McIntyre PB; Palmu AA;
Pediatr Infect Dis J; 2019 Aug; 38(8):860-865. PubMed ID: 30985507
[TBL] [Abstract][Full Text] [Related]
13. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.
Richter L; Schmid D; Kanitz EE; Zwazl I; Pöllabauer E; Jasinska J; Burgmann H; Kundi M; Wiedermann U
PLoS One; 2019; 14(1):e0210081. PubMed ID: 30629620
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization.
Loo JD; Conklin L; Fleming-Dutra KE; Knoll MD; Park DE; Kirk J; Goldblatt D; O'Brien KL; Whitney CG
Pediatr Infect Dis J; 2014 Jan; 33 Suppl 2(Suppl 2 Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants 0 A Landscape Analysis of Evidence Supportin g Different Schedules):S161-71. PubMed ID: 24336058
[TBL] [Abstract][Full Text] [Related]
15. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
16. Determining the pneumococcal conjugate vaccine coverage required for indirect protection against vaccine-type pneumococcal carriage in low and middle-income countries: a protocol for a prospective observational study.
Chan J; Nguyen CD; Lai JYR; Dunne EM; Andrews R; Blyth CC; Datta S; Fox K; Ford R; Hinds J; La Vincente S; Lehmann D; Lim R; Mungun T; Newton PN; Phetsouvanh R; Pomat WS; Xeuatvongsa A; von Mollendorf C; Dance DAB; Satzke C; Muholland K; Russell FM;
BMJ Open; 2018 May; 8(5):e021512. PubMed ID: 29776921
[TBL] [Abstract][Full Text] [Related]
17. Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya.
Flasche S; Ojal J; Le Polain de Waroux O; Otiende M; O'Brien KL; Kiti M; Nokes DJ; Edmunds WJ; Scott JAG
BMC Med; 2017 Jun; 15(1):113. PubMed ID: 28592303
[TBL] [Abstract][Full Text] [Related]
18. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
Izurieta P; Bahety P; Adegbola R; Clarke C; Hoet B
Expert Rev Vaccines; 2018 Jun; 17(6):479-493. PubMed ID: 29241390
[TBL] [Abstract][Full Text] [Related]
19. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study.
Jayasinghe S; Chiu C; Quinn H; Menzies R; Gilmour R; McIntyre P
Clin Infect Dis; 2018 Jul; 67(3):367-374. PubMed ID: 29471432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
